Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Bayer Healthcare is ending three clinical studies of Trasylol for non-CABG indications. Release
Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.
Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.
The series C positions Lava to begin assessing the drugs in proof-of-concept clinical trials in solid tumors and hematological malignancies.